Hetal Abhay Shah

Dr. Hetal Abhay Shah

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

28 October 2020 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
HSHetal Abhay Shah
Hetal Abhay Shah
DSDhananjaya Saranath
Dhananjaya Saranath
Vinuthaa MurthyVinuthaa Murthy
Vinuthaa Murthy
The p53 gene is mutated in greater than 50% of several human cancers including bladder urothelial carcinoma, lung adenocarcinoma, colorectal carcinoma, and oral cancer. Mutations in the p53 gene occur predominantly in the DNA-binding domain causing loss of function and accumulation of dysfunctional p53 protein in tumors by hetero-oligomerization with the wild type p53. Thus an in silico approach for the rational design of potent, pharmacologically active small drug-like compounds targeting mutated p53 was undertaken. Molecular dynamics simulations of the wild type p53 monomer and p53 mutants R175H and R248Q were performed using Discovery Studio v3.5. Phase was used to generate pharmacophore models and the sitemap generated pocket was used to screen the Maybridge HitFinderTM library using Schrodinger Suite. We identified ten compounds (Cmpd-1 to Cmpd-10) that showed preferential binding to p53 mutants, and their pharmacokinetic profiles complied with the ADMET rules. Cmpd-4 and Cmpd-8 demonstrated binding with mutated p53 at cysteine 124, similar to the mutant p53 reactivating compound APR-246 (PRIMA-1Met) for functional restoration of the mutant p53. We propose the identified compounds as suitable drug candidates against mutated p53 protein, with the specific small drug-like molecules as either single drugs or in combination with lower doses of additional cytotoxic drugs, consequently reducing adverse side effects in patients. Communicated by Ramaswamy H. Sarma

26 August 2019 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
HSHetal Abhay Shah
Hetal Abhay Shah
DSDhananjaya Saranath
Dhananjaya Saranath
SPSultan Pradhan
Sultan Pradhan

26 October 2018 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
HSHetal Abhay Shah
Hetal Abhay Shah
DSDhananjaya Saranath
Dhananjaya Saranath
SDSoma Das
Soma Das
PKPrashant S. Kharkar
Prashant S. Kharkar
AKAnjali Karande
Anjali Karande

29 April 2026 in Scientia Pharmaceutica
Verified
Journal Article
Open access
PDF file
VAValmik Sopan Aware
Valmik Sopan Aware
SRSHREYA RAO
SHREYA RAO
SKSanjay Pundlik Khairnar
Sanjay Pundlik Khairnar
APArati Prabhu
Arati Prabhu
HSHetal Abhay Shah
Hetal Abhay Shah
SMSonal Manohar
Sonal Manohar
Background: Cancer is a leading cause of mortality worldwide. Discovery of small molecules as anticancer agents is an active area of research, as these molecules possess the remarkable ability to interact with specific targets within cancer cells. Objectives: In vitro anticancer activity of six hit derivatives from a series of 2-phenyl-substituted 4-amino–6, 7-dihydro-5H-cyclopenta[d]pyrimidines was tested against human cancer cell lines, viz., A549 (human lung cancer) and A431 (human skin cancer). Methods: Cytotoxicity was evaluated for six hits by the standard MTT assay. Further, their effect on clonogenic potential and cell cycle was tested using colony forming assay and flow cytometric analysis, respectively. Apoptosis-inducing potential was confirmed using Caspase-3/7 Glo assay and detection of cleaved caspase-3 by immunofluorescence. The effect on cell migration was tested using a wound healing assay. Target analysis, Molecular docking and ADMET simulations were performed to identify molecular targets, interactions and assess pharmacokinetic profiles. Results: Specific derivatives showed good to moderate cytotoxicity against A549 and A431 (with average IC50 in the range of ~30 µM), and these hits led to apoptosis and G1 arrest in these cell lines, respectively. Furthermore, identified hits inhibited cell migration in A549 cells. Computational consensus target analysis identified EGFR and CDK2 as high-confidence targets. Docking studies indicated favorable interactions and stability, whereas the ADMET analysis confirmed the drug-likeness and optimal pharmacokinetic and safety profiles of the small molecules. Conclusions: Our current study demonstrates the anticancer potential of novel pyrimidine derivatives. We envisage the use of these small molecules as promising anticancer agents, particularly in skin and non-small cell lung cancer.

25 September 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
HSHetal Abhay Shah
Hetal Abhay Shah
MKMaushmi S. Kumar
Maushmi S. Kumar
The tumor microenvironment is a complex ecosystem where the extracellular matrix serves as a dynamic signaling hub and regulates tumorigenesis. Thrombospondin-2 (THBS2), a matricellular extracellular matrix protein, has traditionally been regarded as an inhibitor of angiogenesis. However, emerging evidence reveals a pleiotropic and paradoxical pro-tumorigenic role of THBS2 in several malignancies. THBS2 has been identified as a multifaceted regulator of critical mechanisms driving cancer progression including angiogenesis induction, vasculogenic mimicry, sustained proliferation, invasion, metastasis, phenotypic plasticity, and immune suppression in aggressive cancers. By modulating diverse signaling pathways, especially the PI3K/AKT/mTOR axis, remodeling the collagenous architecture of the extracellular matrix, and formation of non-endothelial vascular channels, THBS2 supports tumor progression and metastasis. This minireview encompasses current research regarding the emerging molecular mechanisms by which THBS2 regulates pro-tumorigenic functions and discusses its role in resistance to therapy. The diagnostic and prognostic value of THBS2, particularly in aggressive cancers, underscores the need for the development of novel therapeutics specifically targeting this deregulated protein.